Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genera inc. - lyofilisaat voor oculonasale suspensie/gebruik in drinkwater - avian infectious bronchitis virus - kippen

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genera inc. - levend verzwakt aviaire infectieuze bursitis virusvaccin, stam vmg 91 - lyofilisaat voor suspensie - avian infectious bursal disease virus (gumboro disease) - kippen

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genera inc. - levend verzwakt aviaire infectieuze bursitis virusvaccin, stam vmg 91; natriumglutamaat (e 621) - lyofilisaat voor oraal gebruik - avian infectious bursal disease virus (gumboro disease) - kippen

Europese Unie - Nederlands - EMA (European Medicines Agency)

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - immunosuppressiva - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz kan worden gegeven als monotherapie in geval van intolerantie voor methotrexaat of wanneer voortgezette behandeling met methotrexaat als ongepast. adalimumab is aangetoond dat het verminderen van de snelheid van progressie van gewrichtsschade, zoals gemeten door de x-ray en verbetering van fysiek functioneren, indien gegeven in combinatie met methotrexaat. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz kan worden gegeven als monotherapie in geval van intolerantie voor methotrexaat of wanneer voortgezette behandeling met methotrexaat als ongepast. adalimumab is niet onderzocht bij patiënten jonger dan 2 jaar. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab is aangetoond dat het verminderen van de snelheid van progressie van perifere gewrichtsschade, zoals gemeten door de x-ray bij patiënten met polyarticulaire symmetrische subtypen van de ziekte en het verbeteren van fysieke functie. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.  paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Europese Unie - Nederlands - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - immunosuppressiva - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. de behandeling van ernstige, actieve en progressieve reumatoïde artritis bij volwassenen die niet eerder behandeld zijn met methotrexaat. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita vermindert de snelheid van progressie van gewrichtsschade, zoals gemeten door de x-ray en verbetert de fysieke functie, indien gegeven in combinatie met methotrexaat. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita kan worden gegeven als monotherapie in geval van intolerantie voor methotrexaat of wanneer voortgezette behandeling met methotrexaat als ongepast (voor de werkzaamheid in monotherapie zie sectie 5. adalimumab is niet onderzocht bij patiënten jonger dan 2 jaar. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita vermindert de snelheid van progressie van perifere gewrichtsschade, zoals gemeten door de x-ray bij patiënten met polyarticulaire symmetrische subtypen van de ziekte (zie hoofdstuk 5. 1) en verbetert de fysieke functie. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 en 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Europese Unie - Nederlands - EMA (European Medicines Agency)

accord healthcare s.l.u. - caspofungine-acetaat - candidiasis; aspergillosis - antimycotica voor systemisch gebruik - de behandeling van invasieve candidiasis bij volwassen of pediatrische patiënten. behandeling of invasive aspergillosis in volwassen of pediatrische patiënten die refractair of intolerant is voor amfotericine b, lipide formuleringen van amfotericine b en/of itraconazole. ongevoeligheid is gedefinieerd als de progressie van infectie of niet verbeteren na een minimum van 7 dagen voorafgaande therapeutische doses van de effectieve antifungale therapie. empirische therapie bij vermoeden van schimmelinfecties (zoals candida of aspergillus) in febriele, neutropaenic volwassen of pediatrische patiënten.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genera inc. - levend lentogeen newcastle disease virus, stam la sota - lyofilisaat voor suspensie - newcastle disease virus / paramyxovirus - kalkoenen; kippen

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genera inc. - levend verzwakt aviaire infectieuze bronchitis virus, stam h120 - lyofilisaat voor suspensie - avian infectious bronchitis virus - kippen

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genera inc. - levend lentogeen verzwakt newcastle disease virus, stam hitchner b1 - lyofilisaat voor suspensie - newcastle disease virus / paramyxovirus - kippen

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

elpen pharmaceutical co. inc. 95 marathonos ave 190 09 pikermi attikis (griekenland) - aripiprazol - orodispergeerbare tablet - acesulfaam kalium (e 950) ; aspartaam (e 951) ; calciumsilicaat (e 552) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; crospovidon (e 1202) ; ijzeroxide rood (e 172) ; magnesiumstearaat (e 470b) ; siliciumdioxide (e 551) ; vanilline ; wijnsteenzuur, (l (+) vorm) (e 334) ; xylitol (e 967), - aripiprazole